We Are Crinetics


Crinetics is a pharmaceutical company that researches, discovers, and develops breakthrough therapies for patients with
rare endocrine diseases or tumors. We foster long-term relationships with healthcare practitioners to learn intimately
about the challenges patients face every day, then focus on developing game-changing therapies that improve their lives
in significant ways.

NANETS 2022 POSTER PRESENTATION


A Phase 2, Randomized, Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Subjects with Carcinoid Syndrome.

Presented by:

Aman Chauhan, M.D., study co-author
Director of NET Theranostics UK Markey Cancer CenterUniversity of Kentucky Healthcare
Friday, October 28, 5:15-7:00PM in The Poster Hall

AbstractPoster
200113amanchauhan134 4 1 uai

CONTACT US


Please fill out the information below and our medical affairs team will reach out to you about Crinetics and our Phase 2 and future Phase 3 studies with paltusotine for the treatment of carcinoid syndrome.

Discovery Pre-Clinical Phase 1 Phase 2 Phase 3
Paltusotine (SST2 Agonist)
Acromegaly (PATHFNDR-1)
Acromegaly (PATHFNDR-2)
Carcinoid Syndrome
Congenital Adrenal Hyperplasia (CAH)
PTH Antagonist, Hyperparathyroidism
SST3 Agonist, Polycystic Kidney Disease
TSH Antagonist, Graves' Disease, TED
Oral GLP-1 nonpeptide, Diabetes, Obesity
Oral GIP nonpeptide, Diabetes, Obesity
SST5 Agonist, Hyperinsulinism
Radionetics, Targeted Radiotherapy | Multiple Solid-Tumor Oncology Company
Discovery Pre-Clinical Phase 1 Phase 2 Phase 3
Paltusotine (SST2 Agonist)
Acromegaly (PATHFNDR-1)
Acromegaly (PATHFNDR-2)
Carcinoid Syndrome
Congenital Adrenal Hyperplasia (CAH)
PTH Antagonist, Hyperparathyroidism
Undisclosed, Polycystic Kidney
TSH Antagonist, Graves' Disease, TED
Undisclosed (Multiple), Diabetes, Obesity
SST5 Agonist, Hyperinsulinism
Radionetics, Targeted Radiotherapy | Multiple Solid-Tumor Oncology Company